Drug Designing: Open Access is a peer-reviewed and open access journal with an aim to provide rapid and reliable source of information in the mode of original articles, review articles, case reports, short communications, etc. in all areas of the field and making them freely available through online without any restrictions or any other subscriptions to researchers worldwide.

The Journal, Drug Designing: Open Access publishes the highest quality scientific articles amalgamating broad range of fields including molecular modeling, clinical research and drug discovery and delivery.

Metabolomics is an emerging field with tremendous potential to improve our understanding of human health and disease, and may led to the development of personalized approaches for disease diagnosis, patient monitoring and treatment response evaluation . Metabolomics has the potential to uncover phenotypic diوٴerences in a very sensitive manner and may become a powerful tool for general drug screening studies. Single-cell analysis is necessary to understand the biological and physiological properties of single cells and multicellular organisms.

Single-cell metabolomics technologies have developed rapidly, reaching a critical point where they can be a valuable tool for systematic characterization of cellular heterogeneity, which in turn has important implications in a wide range of biomedical fields such as disease characterization. Нis development has been enabled to some extent by engineering sciences, among which microsystem technologies are a major driving force. One of the best examples of the need for single-cell metabolomics is cancer. It only takes one abnormal cell in the whole body that contains 30 trillion cells to cause cancer. Single-cell metabolomics analysis has the potential to help in early detection of medical conditions involving modifications in the cellular functions such as cancer genesis and progression. Нere is also a need to diوٴerentiate between cells with diوٴerent metabolomes within the same cancer to evaluate phenotype heterogeneity, and in eوٴect, prevent drug resistance or discover new, more eوٴective therapeutics

We publish the article related to the effects of dual diagnosis, Treatment, outcomes of the treatment. We invite different types of science communications including original research article, systematic reviews, short note communications, case reports, Editorials, letters to the Editors and expert opinions & commentaries from different regions for publication.

Manuscripts can be published through the online link. Or to the given below Email Id.

With Regards,
Sherry Peterson 
Drug Designing: Open Access
Editorial Manager
Email: drugdesign@longdom.org
Whats App:+1-947-333-4405